Paul A. Mahon, Executive Vice President and General Counsel at United Therapeutics Corp (NASDAQ:UTHR), recently sold 7,700 shares of the company's common stock. The shares were sold at an average price of $374.37, totaling approximately $2.88 million. The transaction comes as United Therapeutics demonstrates strong financial performance, with an impressive 88.94% gross profit margin and a 70.25% year-to-date return. According to InvestingPro, the company maintains excellent financial health with multiple positive indicators.
In addition to the sale, Mahon exercised share tracking awards, acquiring 7,700 shares of common stock at a price of $163.30 per share. These transactions were part of a pre-arranged 10b5-1 trading plan. Following these transactions, Mahon holds 36,710 shares directly. Trading at a P/E ratio of 15.18 and near its 52-week high of $417.81, UTHR shows promising metrics. InvestingPro subscribers can access 12 additional key insights about United Therapeutics' financial outlook and valuation.
In other recent news, United Therapeutics Corp. reported a 23% increase in third-quarter revenue for 2024, reaching $749 million, primarily due to the sales of key products Tyvaso, Orenitram, and Unituxin. Ladenburg Thalmann maintained a Neutral rating on the company's stock, raising the price target to $344, primarily due to Tyvaso's strong sales performance. Meanwhile, H.C. Wainwright reaffirmed a Buy rating and increased the price target to $425, reflecting a positive outlook on Tyvaso's continued strong performance and United Therapeutics' strategic positioning in anticipation of rising competition.
Despite a slight decrease in Remodulin sales, United Therapeutics remains confident in its long-term viability as a preferred treatment for pulmonary arterial hypertension. The company also completed a $1 billion accelerated share repurchase program, demonstrating its commitment to returning capital to shareholders.
According to recent analyst notes, United Therapeutics is well-positioned for future growth, eyeing upcoming clinical milestones and a potential FDA decision on its Centralized Lung Evaluation System in 2025. These recent developments reflect the company's strategic focus on expanding commercial ventures and research and development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.